VEGFR3/Flt-4 Antibody (LY3022856) [Janelia Fluor® 669]

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28809JF669

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Validated:

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Janelia Fluor 669

Antibody Source

Recombinant Monoclonal Human IgG1 Clone # LY3022856

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all VEGFR3/Flt-4 Antibodies »

Product Summary for VEGFR3/Flt-4 Antibody (LY3022856) [Janelia Fluor® 669]

Immunogen

VEGFR3 / FLT4

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Applications for VEGFR3/Flt-4 Antibody (LY3022856) [Janelia Fluor® 669]

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: VEGFR3/Flt-4

FLT4, a VEGF Receptor type protein kinase, is an endothelial cell-specific receptor. Binding of the extracellular domain of FLT4 to the vascular endothelial growth factor-related protein VEGF-C stimulates tyrosine phosphorylation and mitogenesis of endothelial cells. FLT4 (-/-) mice have been shown to have defective blood vessel development in early embryos and to experience cardiovascular failure at embryonic day 9.5. A mutation in the FLT4 gene has been implicated in human hereditary lymphedema type I. Similarly, a mutation in the conserved catalytic domain of FLT4, in close proximity to the FLT4 mutations in human primary lymphedema, has been linked to the Chy mouse mutant.

Long Name

Vascular Endothelial Growth Factor Receptor 3

Alternate Names

Flt-4, FLT4, VEGF R3

Gene Symbol

FLT4

Additional VEGFR3/Flt-4 Products

Product Documents for VEGFR3/Flt-4 Antibody (LY3022856) [Janelia Fluor® 669]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for VEGFR3/Flt-4 Antibody (LY3022856) [Janelia Fluor® 669]



Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.